Lolita Camp
Nurse Practitioner · New Orleans, LANPI 1083782734
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Gilead at 29.2% of the total. 2025 is the largest year on record at $2,771, 2.5 times the $1,128 reported in 2021. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $99.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Teva Pharmaceuticals USA, Inc.$851
- AstraZeneca$849
- Sanofi$684
- AbbVie$579
- Medtronic$399
- plus $4K from 28 others
What the payments were for
- Food & beverage$10,218100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 36 | $2,984 |
| Teva Pharmaceuticals USA, Inc. | 7 | $851 |
| AstraZeneca(2 entities) | 8 | $849 |
| Sanofi | 6 | $684 |
| AbbVie | 5 | $579 |
| Medtronic | 3 | $399 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $300 |
| Neurelis, Inc. | 3 | $299 |
| Abbott | 2 | $290 |
| Madrigal Pharmaceuticals | 2 | $270 |
| Dexcom, Inc. | 2 | $239 |
| Viiv Healthcare Company | 2 | $227 |
| Bayer | 1 | $140 |
| Corcept Therapeutics | 1 | $125 |
| Amgen | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Sanofi Pasteur Inc. | 1 | $125 |
| Novo Nordisk | 1 | $123 |
| Xeris Pharmaceuticals, Inc. | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Idorsia Pharmaceuticals US Inc | 1 | $120 |
| Agile Therapeutics, Inc. | 2 | $111 |
| Insmed, Inc. | 1 | $102 |
| Impel Pharmaceuticals Inc. | 1 | $100 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $100 |
| Nevro Corp. | 2 | $98 |
| Jazz Pharmaceuticals Inc. | 1 | $97 |
| Lilly USA, LLC | 1 | $95 |
| Neurocrine Biosciences, Inc. | 1 | $94 |
| Mannkind Corporation | 1 | $84 |
| Boston Scientific | 1 | $71 |
| Theratechnologies Inc. | 1 | $60 |
| Shionogi Inc | 1 | $52 |
| Exact Sciences | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$615
- DUPIXENT$484
- Austedo XR$484
- VRAYLAR$374
- Descovy$347
- LifeVest$300
- REZDIFFRA$270
- INTERSTIM$264
- Strensiq$244
- FABRAZYME$243
- FREESTYLE LIBRE 3$163
- Kerendia$140
- INTELLIS ADAPTIVESTIM$135
- FreeStyle Libre 2$128
- Humira$125
- AJOVY$125
- Korlym$125
- Yeztugo$125
- AUSTEDO$125
- Repatha$125
How this compares
$10,218 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 17 | $463,952 |
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 21 | $183,681 |
| Tenofovir Disoproxil Fumarate | 21 | $649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $2,984 | $463,95217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in New Orleans
- Julia SirenNew Orleans$14K
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Ellen GentileWest Monroe$31K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.